摘要
目的观察益气通脉方联合阿托伐他汀治疗缺血性中风恢复期气虚血瘀型合并颈动脉粥样硬化斑块的疗效。方法将80例动脉粥样硬化性脑梗死患者随机分为治疗组和对照组,对照组给予阿托伐他汀钙片及其他常规治疗,治疗组在对照组基础上加用益气通脉方,疗程12周。检测临床疗效、NIHSS评分、Barthel指数评分、中医证候评分、血脂4项、血清APN、CTRP5以及颈动脉彩超指标。结果治疗后治疗组总有效率(95.0%)高于对照组(80.0%)(P<0.05);两组治疗后NIHSS评分、中医证候评分降低(P<0.05),Barthel评分提升(P<0.05),斑块明显改善(P<0.05),血脂4项、CTRP5水平均降低(P<0.05);血清APN升高(P<0.05),治疗组较对照组方案更优(P<0.05)。结论益气通脉方联合阿托伐他汀钙片的治疗效果更佳,说明联合用药的共同作用较好。
Objective To study the Yiqi Tongmai formula combined with atorvastatin in treating carotid atherosclerotic plaque of qi deficiency and blood stasis type in the recovery period of ischemic stroke.Methods Eighty patients with atherosclerotic cerebral infarction were randomly divided into treatment group and control group.The control group was given atorvastatin calcium tablets and other conventional treatments,while the treatment group was given Yiqi Tongmai formula based on the control group,and the course of treatment was 12 weeks.Clinical efficacy,NIHSS score,Barthel index score,TCM syndrome score,four items of blood lipid,serum APN,CTRP5,and carotid artery color Doppler ultrasound indexes were detected.Results After treatment,the total effective rate of the treatment group was higher than that of control group(P<0.05).The NIHSS score and TCM syndrome score of the two groups were decreased(P<0.05);Barthel score was elevated(P<0.05);The improvement of plaque was significantly better than that of the control group(P<0.05).The levels of four blood lipids and CTRP5 were all reduced(P<0.05).Serum APN was increased(P<0.05).The treatment group had a better regimen than the control group(P<0.05).Conclusion Yiqi Tongmai Formula combined with atorvastatin calcium tablets has a better therapeutic effect,which indicates that the combined drugs have a better co-action effect.
作者
庞伯通
南淞华
陈芳芳
葛文静
崔应麟
PANG Botong;NAN Songhua;CHEN Fangfang;GE Wenjing;CUI Yinglin(The Second Clinical Medical College,Henan University of Traditional Chinese Medicine,Zhengzhou 450000,China;Hall of Famous Doctors,Henan Provincial Hospital of Traditional Chinese Medicine,Zhengzhou 450002,China)
出处
《医药导报》
CAS
北大核心
2023年第10期1511-1516,共6页
Herald of Medicine
基金
河南省重点研发与推广专项(科技攻关)项目(212102311123)
河南省中医药科学研究专项课题(2019ZY2003)
国家中医药科学技术研究专项(GZY-KJS-2021-017)。
